Our Breakthrough Findings
In the Palm of Your Hand
In the Palm of Your Hand
Our success in the lab has allowed us to develop powerful, revolutionary products to support your best efforts to get healthy and stay healthy. Our goal is to change global health for the better. We’d like to start with you.
Metabolic syndrome is a cluster of conditions that occur together, increasing your risk of heart disease, stroke, and Type 2 diabetes. These conditions include increased blood pressure, high blood sugar, excess body fat around the waist, and abnormal cholesterol or triglyceride levels.
In 1996, Dr. W. Wayne Lautt announced that he had discovered a hormone produced by the liver. He observed the impact of this hormone on glucose uptake and later named the hormone hepatalin***
In young, healthy humans, hepatalin does two-thirds of the heavy lifting of reducing elevated blood sugar. As we age and ingest more refined sugar, we destroy the production of hepatalin in our bodies.
We need the right balance of hepatalin and insulin to stay healthy.
When we eat a meal, our bodies absorb energy from food as glucose, which is a form of sugar. Some of that glucose is used immediately as energy. What happens to the excess glucose helps to determine our well-being. Some of the glucose is stored in our muscle cells as “glycogen”; some of it is stored in fat cells as "triglycerides". If our nutrient partitioning is optimal, our muscles take most of the glucose. If our nutrient partitioning is poor, more glucose gets stored as fat.
After extensive study, it became clear to Dr. W. Wayne Lautt that hepatalin causes excess glucose to be taken up by muscle. Once the liver cannot sufficiently produce hepatalin, our pancreas creates additional insulin, causing nutrient energy to be partitioned into fat.
In the academic literature, hepatalin is known as hepatic insulin-sensitizing substance (the “HISS” hormone). “HISS” and “hepatalin” are interchangeable terms.
Feeding results in an increase of hepatic glutathione (GSH) and a parasympathetic signal to the liver that acts, via acetylcholine (ACh), on muscarinic receptors to activate nitric oxide (NO) release. Both of these signals are permissive and both are needed in order for insulin to cause the release of HISS.
The blockade of any portion of these pathways leads to blockade of HISS release and a state of HISS-dependent insulin resistance. HISS release is physiologically regulated to be absent in the fasted state, but when HISS release is not activated by feeding, its absence is suggested to account for postprandial hyperglycemia, hyperinsulinemia, hyperlipidemia, and increased oxidative stress.
Chronic lack of HISS action results in a progressive and predictable series of homeostatic dysfunctions typical of obesity and Type 2 diabetes.
Lautt, Wayne & Wang, Hui. (2015). Obesity as an Early Symptom of the AMIS Syndrome. Journal of clinical medicine. 3. 1178-98. 10.3390/jcm3041178.
Through many years of research, Dr. W. Wayne Lautt and his team have developed a powerful combination of compounds that support healthy liver function and strengthen your body’s ability to metabolize nutrients
effectively—key factors in the preservation of metabolic health.
While each ingredient will benefit your overall health and wellness, SciMar NuPa Daily's delayed-release formulation delivers all of the active ingredients at the right moment, thereby working to support your metabolism at the cellular level. By starting your day with SciMar NuPa Daily, you are supporting your best efforts to get healthy and stay healthy.